Physician profile
Thomas J Robison
NPI 1518916279
$1,970.50
in general payments reported to CMS, 2019-2025
23 companies · $21.19 in 2025
The $21.19 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $93.09 · 2021: $50.00 · 2023: $418 · 2024: $1,020 · 2025: $21.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $423.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $179.61 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $175.20 | 2019-2024 | |
| Abbvie INC. | $170.92 | 2023-2024 | Qulipta |
| Astrazeneca Pharmaceuticals Lp | $167.91 | 2023-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $146.15 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $132.25 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $70.08 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $60.67 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Lundbeck LLC | $56.71 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $53.49 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $51.87 | 2023-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $44.31 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $43.87 | 2024 | |
| Arbor Pharmaceuticals, INC. | $36.46 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.31 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $29.15 | 2023 | Quviviq |
| Corcept Therapeutics | $23.19 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $15.71 | 2020 | |
| Nevro Corp. | $14.74 | 2024 | Senza |
| Medtronic Vascular, INC. | $14.59 | 2019 | |
| Bausch Health US, LLC | $14.15 | 2020 | |
| Amarin Pharma, INC. | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.